Deloitte Consulting LLP
Ken Hutt has 25 years industry and consulting experience working with life sciences, high-tech, and telecom companies. Dr Hutt joined Deloitte in 1998 and is a corporate strategy partner working with the company’s largest and most diversified telecom, high-tech and healthcare clients. He established Deloitte’s Innovation and Growth practice. This practice takes the core ideas from disruption theory and applies them within a big company environment with the aim of making growth a much more repeatable and predictable process. Dr Hutt is also a member of the US Executive Committee and has been instrumental in leading Deloitte’s internal strategy program.
Dr Hutt is a native of Scotland and graduated from the University of St. Andrews. He subsequently completed his Ph.D. in Physics from the University of Cambridge.
Chief Marketing Officer, Spec. Pharma.
Steve Carchedi is Chief Marketing Officer for General Electric (GE) Healthcare where he is responsible for leading worldwide marketing for the Medical Diagnostics (MDX) business. GE Healthcare MDX is a $1.8 Billion pharmaceuticals business focused on the development and commercialization of pharmaceutical diagnostic (in vivo and in vitro) and Radiopharmaceutical agents for Oncology, Neurology and Cardiology.
Previously, he served as Senior Vice President Specialty Business Unit and headed commercial operations for Endo pharmaceutical company’s $100MM specialty pharmaceutical business. Prior to joining Endo, Steve was Head of Commercial Operations (COO) at Enzon Pharmaceuticals, a specialty oncology company, reporting directly to the Chairman of the Board. Before his work at Enzon, Steve served as Franchise Vice President, Johnson & Johnson McNeil Consumer & Specialty Pharmaceuticals. Steve held positions at Eli Lilly & Company and Bristol Myers Squibb earlier in his career.
Steve received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University.
SVP and Chief Medical Officer
Jon R. Cohen, M.D., is Senior Vice President, Chief Medical Officer, and Director of the Hospital Services for Quest Diagnostics. Quest Diagnostics, with annual revenues of over $7.5 billion, is the world’s leading provider of diagnostic testing, information and services.
Prior to joining Quest Diagnostics in March 2009, Dr. Cohen served as Senior Advisor to New York Governor David A. Paterson and was responsible for all policy and strategic planning. In 2006, he was a candidate for Lieutenant Governor of New York; his campaign platform centered on the healthcare crisis and substantive healthcare reform.
Dr. Cohen served for six years as Chief Medical Officer and Senior Vice President at North Shore-Long Island Jewish Health System, the nation's fourth-largest nonprofit health system. He has held senior professional appointments, including Professor of Surgery at the Albert Einstein College of Medicine and Senior Lecturer at Columbia University's Mailman School of Public Health.
Dr. Cohen is a vascular surgeon, having completed his residency in surgery at New York Presbyterian Hospital/Weill Cornell Medical Center and vascular surgery fellowship at the Brigham and Women's Hospital at Harvard Medical School. He has published over 100 peer-reviewed professional articles, authored two books andhas spent more than two decades in the healthcare field as a practicing surgeon.
Dr. Cohen has an extensive background in federal and state healthcare policy. He has spoken regularly on health and healthcare issues, authored policy articles for major newspapers and served as a guest commentator on leading broadcast media. In 2010, he was named as one the nation’s top 50 most powerful physician executives by Modern Healthcare.
Senior Vice President, Strategy and Business Development
C.R. Bard, Inc.
David Gottlieb joined Bard as Senior Vice President, Strategy and Business Development in January, 2012.
Before joining Bard, David was most recently an independent management consultant offering strategic assessment and transaction advisory services to leading medical technology companies. At the end of 2003, he retired as the Global Head of Medical Technology Corporate and Investment Banking for Banc of America Securities LLC, where he was responsible for the sector team covering nearly 300 companies in the global medical device and hospital supply industry as well as the life science tools, in-vitro diagnostics and diagnostic imaging industries. In addition, he was jointly responsible for the entire Health Care Corporate and Investment Banking Group. Previously, David held a number of positions overseeing investment banking for life sciences companies, including at UBS Investment Bank and Kidder, Peabody & Co. Incorporated.
He has served as a member of the Board of Directors of Abiomed Incorporated as well as a number of community organizations.
David holds a Master in Business Administration degree from Columbia Business School and a Bachelor of Arts degree from Connecticut College.
Vice President, Clinical Marketing
As Vice President of Clinical Marketing, Ryan Rhodes leads the company’s strategic planning and execution for a number of key medical specialty areas including Gynecology, General Surgery, Head and Neck Surgery, and Urology. Mr. Rhodes joined Intuitive Surgical in 2002 as the Director of Urology Marketing.
Prior to joining Intuitive, Mr. Rhodes held various roles of increasing responsibility at Ethicon Endo-Surgery including Marketing Manager, Training Manager, Clinical Education Specialist and Division Sales Manager. He holds a BA degree from San Diego State University in Public Administration.
Mark Page is a Managing Director of Credit Suisse in the Global
Healthcare Group within the Investment Banking division, based in New
York City. He is responsible for the firm's U.S. Medical Device
investment banking franchise as well as leads a number of the firm's
ex-U.S. medical device client relationships.
Mr. Page has over 16 years of financing and strategic transaction
experience completed for a wide spectrum of healthcare clients. Within
medical devices and diagnostics, Mr. Page has worked with and announced
transactions for companies such as Alere, Baxter, Bio-Rad, Biomet,
Boston Scientific, Celera, DJO, Getinge, Insulet, Lifecell, Kinetic
Concepts, Medtronic, NxStage Medical, Proxima Therapeutics (now
Hologic), Synthes, TomoTherapy, and Zimmer.
Mr. Page joined Credit Suisse in July 2010. Prior to that experience,
Mr. Page spent the majority of his career at Merrill Lynch & Co. as a
healthcare investment banker focused on the medical devices sector.
Mr. Page holds a BA in Economics from Haverford College and an MBA from
the Wharton School at the University of Pennsylvania.